Sangamo BioSciences appoints Geoffrey Nichol executive VP of R&D
This article was originally published in Scrip
Sangamo BioSciences, a company focused on research and development of novel DNA-binding proteins for therapeutic gene regulation and modification, has appointed Dr Geoffrey Nichol executive vice-president of R&D. Dr Nichol most recently served as senior vice-president of product development at Medarex.
You may also be interested in...
Almirall has launched its irritable bowel syndrome drug Constella (linaclotide) in six European countries, with several other launches planned for later this year.
Dermira, a dermatology-focused biotech, has raised $35m in a series B financing.
Clovis Oncology has raised its public offering, announced 11 June, from $170m to $240m.